Stockreport

OS Therapies Provides First Half 2026 Corporate Outlook [Yahoo! Finance]

OS Therapies Incorporated  (OSTX) 
PDF or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma (Metastatic Osteosarcoma Program) under Accelerated Approval Program Biomarker data from Phase [Read more]